Orexigen Therapeutics, Inc., Novo Nordisk A/S Seek To Enter Still Struggling Obesity Market This Week

Drugmakers aren’t giving up on a pharmaceutical remedy for America’s obesity woes even as sales for much-anticipated weight-loss pills have fallen short of estimates.

The Food and Drug Administration is scheduled to decide by Sept. 11 whether to approve Orexigen Therapeutics Inc. (OREX)’s obesity drug, the same day the agency is convening its advisers to discuss an injection to combat growing waistlines from Novo Nordisk A/S. (NOVOB)

These potential therapies would follow Belviq from Arena Pharmaceuticals Inc. (ARNA) and Eisai Co. (4523) approved in June 2012, the first weight-loss pill cleared in 13 years, which was followed three weeks later by Vivus Inc. (VVUS)’s Qsymia.

Help employers find you! Check out all the jobs and post your resume.